{
    "links": "https://www.ycombinator.com/companies/eugit-therapeutics",
    "name": "Eugit Therapeutics",
    "headline": "Enabling Tissue Targeting of Therapies",
    "batch": "S22",
    "description": "Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\r\n\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).",
    "activity_status": "Active",
    "website": "http://www.eugittx.com",
    "founded_date": 2022.0,
    "team_size": 2.0,
    "location": "San Carlos, CA",
    "group_partner": "Jared Friedman",
    "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:cell-therapy; industry:synthetic-biology; industry:therapeutics; industry:oncology; industry:biotechnology",
    "founders": [
        {
            "name": "Nizar Batada, Founder",
            "description": "Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.",
            "linkedin": "http://linkedin.com/in/nizar-batada"
        }
    ],
    "status": true,
    "generated_description": "**Eugit Therapeutics: A Brief Overview**\n\nFounded in 2022 and nurtured in the Y Combinator Batch S22, Eugit Therapeutics is on a mission to revolutionize the treatment of tissue-specific inflammatory diseases. The company is tackling the prevalent issue of non-specific drugs that lead to toxicity and failures during clinical trials, a problem that significantly affects millions of people diagnosed with conditions like Inflammatory Bowel Disease (IBD).\n\nAt the heart of Eugit's strategy is their innovative platform, TAGHOME. This technology utilizes T cell receptors to deliver therapeutics directly to the affected tissues. The goal is clear\u2014enhance safety and improve the efficacy of treatments, which could be game-changing for the approximately 3.1 million individuals in the U.S. suffering from IBD. They're keen to kick off clinical trials within the next two years, which is an exciting timeline for anyone following the landscape of biotechnology.\n\nThe company is co-founded by notable figures including George Church from Harvard, a pioneer in genomics and synthetic biology. The team comprises just two full-time employees at their headquarters in San Carlos, California, but they pack a punch with their impressive backgrounds. Nizar Batada, the CEO, has a PhD from Stanford and experience in computational genomics and immunology, while Yoshi Fukazawa, the VP of Research, brings expertise in disease and functional immunology from his time at Cytek.\n\nWith a focus on cell therapy, synthetic biology, therapeutics, oncology, and biotechnology, Eugit Therapeutics is poised to make a meaningful impact in the therapeutic landscape.\n\nFor more information, you can check out their website [here](http://www.eugittx.com). Keep an eye on them; this is a company with a mission that resonates with many and a clear path forward.",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/4d2649cf044d78d3cddd3824828944b7d1e62ec9.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAEHIR6H6F%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191321Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDt736ZW5EfzagAz1eKRSs%2FW4TfHu28RBSFaRNkZ9h47gIhANt6WXtwkgL07bQKDKYDGFxYKx7WOO9JX0BqaYrXnKNbKu4DCNz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMMDA2MjAxODExMDcyIgx8TqkMwTM2PLcRmr4qwgPGGtQBXv7gs7%2BXGteI1gQk%2FjkbIHwQ5hCKXJKVmVAPw3MeVLhZyp8Nf5%2FYigbwE%2BrFR7aZWKjrs7HxAE0JWit5dlINZLjZK%2BS%2FwMaCqoj%2BFDN0gw9iiAPu4Xn5c3b%2BuZe%2F5%2Flfk0EuxZAXVsZtShxXZy%2FERPQ0v%2FRZxSz5qUoaXpL1zj6VWdWVzoI7%2FPlB3bgJ2PpiF7DN%2BJeDsJPx%2FoKTo5ehP9pOeGbMNxoeegVJsCJ3zvzO3o4fcZYIf6c5iIJwM1Ot3Gg7Z3v9oLZjSRU%2FaRLL5j4n3II7DaroOCEVfPlWzTyZM7SNFZZAFSKM8vLKj1VdTr9s3How41zluf%2FOIp7sGNhG%2FjuYJoG%2FmkLFIlYP4wbGrLO69AWnenZyfi1UhAiV6N%2BlAqGnqvpOJh4vq8uNh2eRnXR%2BMVXdq9oVYkm7XFgprL5PDC4ULLyBWqA6kca4z7F4H56nkT%2FsDtT8ek2VOIRIv1Zgcz%2BeeVG7F7AHS4bdbR6eZ3ChY1iQhfPBErh4OiFQM7IqiUKw%2B1CTpvL68xcVN5gjiaDH0Jotw%2BUcW9dMSg9py8xH8qgyiWG5w3dDj9xaoA2G3NMYq6JOGKMwwIrjvQY6pAHDH54nhADhmb7YSEGxHkL3pqs%2B6aYOExStWbzLKzRb3lb2DAgGG8uU9COt8%2FqUEOtOcszTKp7yuCJwMVkfI7PDZ74h9uiRkRxjtH7%2BLlE1xrfd%2FrIq%2B%2BZr9hSFqZ9MUQ4yNHesyx2FYDbsIfCW9ntlrpmZUHCcrzpQDfufsAFcpe%2FudVT3tUqiF8WCN1Vd%2Bx%2FQ9d3i1HvBcJWV9AYAwM0W22VM%2BA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=bf9ca7c143047035b299e5d512f53de43e445544467ea53ef8225ceae632fcad",
    "social_links": [
        "https://www.linkedin.com/company/eugit"
    ],
    "logo_path": "data/logos\\Eugit_Therapeutics_logo.png"
}